Please select the option that best describes you:

How would you treat a patient with metastatic NSCLC >50% PDL-1 positive AND an EGFR or ALK gene mutation/rearrangement in the first-line setting?   

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequence in some patients?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Yuma Regional Medical Center Cancer Center
Would you add immunotherapy to 2L chemotherapy in ...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more